Six Patents Issued in 2025 for the use of Stabilized Platelets for Surgical and Coagulopathic Bleeding and for Drug Delivery
Rockville, Md. (April 6, 2026) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics, guided by its mission that no one should die from controllable hemorrhage, today announced the issuance of multiple United States Patents covering Freeze-Dried Platelet-Derived Hemostat Technology (CLPH-211) and Frozen Activated Platelets (CLPH-511) Technology for multiple method of uses and select compositions of matter. Together, these milestones underscore Cellphire’s progress in establishing a protected, scalable platelet therapeutic platform anchored by CLPH-511. This platform transforms platelet availability from a fragile, just-in-time supply into a durable therapeutic that improves readiness, reduces waste, and prevents care disruption, while advancing toward late-stage development and commercialization.
Cellphire has expanded the patent protection surrounding its FPH technology with several newly issued U.S. patents: US 12,370,219 B2 (issued July 29, 2025), which includes composition-of-matter claims for FPH. In addition, US patent 12,295,972 B2 (issued May 13, 2025) includes claims directed to FPH methods of use across a range of clinical settings, including use in patients receiving antiplatelet therapies.
Additional U.S. patents supporting the FPH technology include, US 12,419,914 B2 (issued Sept. 23, 2025) that is directed to methods of treating bleeding in patients receiving combined antiplatelet and aspirin therapy, and US 12,290,532 B2 (issued May 6, 2025) that covers methods of treating von Willebrand disease. Collectively, these issued U.S. patents provide protection for FPH across key patent categories, including composition, methods of use, and manufacturing processes. The FPH technology has also received patent grants in major international jurisdictions covering compositions, methods of use, and processes of manufacture.
“The continued expansion of our patent portfolio across composition, methods of use, and manufacturing reflects a deliberate and strategic approach to protecting our core technologies,” said Runa Shah-Qaderi, IP Manager at Cellphire Therapeutics. “These newly issued patents strengthen the foundation of our platelet-based platform and support the continued development of our programs as they advance through clinical evaluation.”
Cellphire has also achieved important patent milestones related to its CLPH-511 technology. US patent 12,378,523 B2 (issued Aug. 5, 2025) covers the method of preparing cryopreserved platelets as delivery agents for siRNA and/or miRNA. In addition, patent EP 3 829 604 B1 (issued Feb. 26, 2025) covers compositions of cryopreserved platelets and methods for their manufacture.
About Cellphire Therapeutics
Cellphire Therapeutics, Inc.’s vision: No one should die from controllable hemorrhage. Cellphire is a private, clinical stage biotechnology company developing next-generation, allogeneic, platelet-derived therapies. Cellphire has a portfolio of platelet-derived biologics including two assets in clinical development: its late-stage biologic CLPH-511, a cryopreserved platelet (CPP) therapy with extended shelf life, and CLPH-211, part of the FPH® family of freeze-dried, platelet-derived hemostatic agents. Once approved, Cellphire’s differentiated technologies will address significant unmet health system and medical needs across various clinical settings including acute bleeding associated with surgery, trauma and traumatic brain injury. For more information, visit www.Cellphire.com.
Rob Woods
VP, Business Operations
RWoods@Cellphire.com